Myopia Management: Slowing Nearsightedness
Five Treatments That Slow Myopia in Children
Low-dose atropine drops (0.01% to 0.05% concentration) are applied once at bedtime to slow myopia progression. According to the AAO, about 90% of children respond to treatment, with studies showing roughly a 50% reduction in progression rate. Asian population studies showed the strongest effects, while North American trials show more modest results at the 0.01% dose.
Higher doses (0.05%) show stronger effects but produce more side effects, including light sensitivity and difficulty focusing up close. Your child's eye doctor starts with a lower dose and may adjust based on response. Treatment continues for at least two years to assess effectiveness.
MiSight 1 day lenses are the first FDA-approved soft contact lens for myopia control in children ages 8 to 12. A three-year clinical trial demonstrated a 59% reduction in myopia progression compared to standard daily lenses (FDA/AAO). Your child wears them during the day and throws them away each night.
Daily disposable lenses reduce infection risk compared to reusable contacts because your child starts with a fresh lens each morning. MiSight works through a dual-focus design that creates a signal to slow eye growth while maintaining clear vision.
Ortho-K uses custom rigid gas-permeable contact lenses worn only overnight. While your child sleeps, the lenses gently reshape the cornea. In the morning, your child removes the lenses and sees clearly during the day without glasses or contacts. Research shows ortho-K reduces axial elongation by up to 50% in children (AAO).
Ortho-K requires consistent nightly wear for the effect to continue. If your child stops wearing the lenses, the cornea returns to its original shape within days and myopia management stops. Hygiene is critical because overnight wear carries higher infection risk than daily disposable lenses.
Specialized spectacle lenses received FDA marketing authorization in 2022 as the first myopia control glasses in the United States. Clinical data showed 71% slower myopia progression on average over two years (FDA, 2022). These lenses are indicated for children ages 6 to 12 starting treatment.
Myopia control glasses appeal to families who prefer a non-contact-lens option. Your child wears them like regular glasses, eliminating hygiene concerns associated with contacts. The lenses look and feel like standard eyeglasses to the child.
Combining low-dose atropine with ortho-K contact lenses was 28% to 38% more effective than either treatment alone in a two-year clinical study (AAO). This approach targets myopia progression through two different mechanisms at the same time.
Your child's eye doctor may recommend combination therapy if a single treatment produces inadequate results. The added complexity of managing two treatments means more frequent monitoring visits and a more detailed daily routine for your child.
How Myopia Management Works
Myopia happens when the eyeball grows too long. All five treatments aim to slow this axial elongation, the increase in eye length that makes nearsightedness worse over time. None of these treatments reverse existing myopia. They reduce the rate at which it gets worse.
The goal is to limit how severe your child's myopia becomes by adulthood. Less myopia at maturity means lower lifetime risk for retinal detachment, glaucoma, and macular degeneration, conditions linked to high myopia.
Earlier intervention yields greater benefit. Starting myopia management before or at early myopia onset gives the treatment more years to work before eye growth stabilizes in the late teens. The AAO recommends discussing options with your child's eye doctor at the first sign of nearsightedness.
Treatment typically continues through the teenage years, when myopia progression tends to slow on its own. Your child's eye doctor monitors progression with regular exams and adjusts the treatment plan based on results.
Your child's eye doctor tracks myopia management by measuring both the prescription (how strong the glasses need to be) and the axial length (how long the eye has grown). Axial length measurements provide the most direct evidence of whether the treatment is slowing eye growth.
A successful treatment does not stop myopia progression entirely. It slows it. If your child's prescription increased by one diopter per year before treatment and half a diopter per year during treatment, the therapy is working even though myopia is still progressing.
Choosing the Right Treatment for Your Child
Children as young as 6 can use myopia control spectacle lenses, which require no special handling. Contact lens options like MiSight and ortho-K work best for children ages 8 and older who can handle lens insertion, removal, and hygiene reliably. Atropine drops work at any age but require a nightly routine.
Your child's maturity matters more than a fixed age cutoff. A responsible 8-year-old may handle contact lenses well, while a 10-year-old who resists routines may do better with glasses or drops. Your eye doctor assesses readiness alongside your observations at home.
Consider your family's daily routine when choosing a treatment. Ortho-K adds nightly lens handling and morning checks. Atropine drops add one bedtime step. MiSight adds morning lens insertion and evening disposal. Myopia control glasses add nothing beyond what regular glasses require.
If your child plays sports, daytime freedom from glasses or contacts is a factor. Ortho-K provides clear daytime vision without eyewear. MiSight contacts stay in during the day. Glasses are the simplest but can be inconvenient for active children.
Myopia management treatments are not always covered by vision insurance because some plans classify them as specialty services. Costs vary by treatment type, provider, and geographic area. Ask your eye doctor's office about pricing and whether your insurance covers any portion of the treatment.
Specialty contact lenses, whether MiSight or ortho-K, require ongoing supply costs and fitting fees. Atropine drops require a prescription, and compounding costs depend on the pharmacy. Myopia control glasses have a one-time lens cost with periodic replacement as the child grows.
The Role of Outdoor Time
Spending at least two hours per day outdoors delays myopia onset and slows progression in children. Bright natural light stimulates dopamine release in the retina, which inhibits the axial elongation that causes myopia (AAO/NEI). This effect comes from outdoor light intensity, not the distance of outdoor viewing.
Outdoor time works as both a preventive measure and a complement to clinical treatments. Children who are not yet myopic benefit from delayed onset. Children already in treatment may see additional slowing of progression.
Recess, outdoor sports, walking to school, and after-school play all count toward the daily two-hour target. The time does not need to be continuous. Two or four separate outdoor periods during the day provide the same benefit as one long session.
Overcast days still provide more light intensity than indoor environments. Your child does not need direct sunlight to benefit. UV-protective sunglasses should be worn to protect from UV radiation while still gaining the myopia-protective benefits of outdoor light.
Myopia Management Questions for Parents
Yes. A two-year study showed that combining low-dose atropine with ortho-K was 28% to 38% more effective than either treatment alone. Your child's eye doctor determines whether combination therapy is appropriate based on how well a single treatment is working.
Treatment continues as long as myopia is progressing, typically through the teenage years. Your eye doctor monitors progression at regular intervals and may adjust or discontinue treatment when eye growth stabilizes, usually in the late teens or early twenties.
No. Myopia management slows progression but does not eliminate existing nearsightedness. Your child still needs vision correction (glasses, contacts, or eventually surgery as an adult). The benefit is reaching a lower final prescription with lower lifetime complication risk.
As of early 2025, a pharmaceutical-grade low-dose atropine formulation (SYD-101) has an FDA action date of October 23, 2025 (Sydnexis, March 2025). If approved, it would be the first FDA-approved drug specifically for pediatric myopia progression. Currently, eye doctors prescribe compounded atropine off-label.
If you stop myopia management before eye growth stabilizes, myopia may progress at its natural rate again. Some studies show a rebound effect, especially after stopping atropine drops, where progression temporarily speeds up. Your eye doctor can discuss the risks of early discontinuation.
Yes. Children with a family history of myopia, limited outdoor time, or extensive near work are at higher risk. An early baseline exam helps your eye doctor identify risk factors before myopia starts, when preventive strategies like increased outdoor time can have the greatest impact.
Start the Conversation With Your Eye Doctor
If your child has been diagnosed with nearsightedness or has risk factors for developing it, ask your eye doctor about myopia management options at the next visit. Earlier intervention produces the best long-term results.